|Articles|August 1, 2002
- Applied Clinical Trials-08-01-2002
Developing New Drugs in 1000 Days
Everybody wants faster cycles and and quicker turnarounds with NDAs. In the U.S., will it soon be possible to go from testing to approval in 1000 days?
Advertisement
Articles in this issue
over 23 years ago
Cross-(Dys)Functional Teamsover 23 years ago
Checking In on Children, Checking Up on Filesover 23 years ago
eSource Reduxover 23 years ago
New User Fee Program Aims to Spur Drug Developmentover 23 years ago
Paper vs. Electronic DiariesNewsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Novo Nordisk’s Phase III OASIS 4 Analyses Highlight Cardiometabolic Benefits of Oral Semaglutide 25 mg
2
Using AI and Tokenized Data to Match Patients to Protocols
3
Eli Lilly’s Phase II Trial of Eloralintide Shows Up to 20% Weight Reduction in Adults With Obesity
4
ACT Brief: Data Strategy, AI Integration, and Rare Disease Milestones Drive Clinical Innovation
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
